<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article88</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/MASTER_DAPT" style="display:block; margin-bottom:10px;">MASTER DAPT Original</a></li>
<h2><strong>MASTER DAPT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Dual Antiplatelet Therapy Duration in High-Bleeding-Risk Patients After Stent Implantation".<br/>
The New England Journal of Medicine. 2021.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
What is the appropriate duration of dual antiplatelet therapy in patients at high risk for bleeding after the implantation of a drug-eluting coronary stent?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
One month of dual antiplatelet therapy was noninferior to the continuation of therapy for at least 2 additional months regarding the occurrence of net adverse clinical events and major adverse cardiac or cerebral events, and resulted in a lower incidence of major or clinically relevant nonmajor bleeding.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/><br/>
<br/>
<h2><strong>Design</strong></h2><br/><br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Patients at high bleeding risk who had undergone implantation of a biodegradable-polymer sirolimus-eluting stent, free from adverse events during the first month post-PCI.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Abbreviated dual antiplatelet therapy (one month duration, n=2295)<br/>
- Standard dual antiplatelet therapy (at least three additional months, n=2284)<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Net adverse clinical events at 335 days.<br/>
- Major adverse cardiac or cerebral events at 335 days.<br/>
- Major or clinically relevant nonmajor bleeding at 335 days.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- The open-label design could introduce bias in reporting or management of outcomes.<br/>
- The results may not generalize to patients with lower bleeding risk or those who receive different stent types.<br/>
- Wide noninferiority margins could potentially miss a modest increase in incidence.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
The trial was funded by Terumo.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
The New England Journal of Medicine, DOI: 10.1056/NEJMoa2108749
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
